Healthcare
Tian'an Pharmaceutical Co., Ltd.(TNPH)
Live Price
Offline$0.0105
+0.00% today
1Y Change
+337.50%
Window
Jun 23, 2025 → Jun 18, 2026
- Market Cap
- —
- Revenue Growth
- 0.0%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 253 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tian'an Pharmaceutical Co., Ltd. (TNPH) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and up 337.5% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow -173.6% with operating margin 0.0% and ROIC 30.8%. Valuation already assumes a fairly strong business story at P/E 1258.6. Stock Foundry combines TNPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
P/E
Above sector median
1258.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is 0.0%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TNPH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TNPH Max Drawdown
-30.33%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TNPH and SPY.
Company Overview
Tian'an Pharmaceutical Co., Ltd.
Other OTC
Tian'an Pharmaceutical Co., Ltd. develops, manufactures, and sells traditional Chinese herbal medicines, including pallets, hard capsules, and soft ointments for the treatment and prevention of diseases in China. It also engages in the research and development of biology goods and health care products. The company's pharmaceutical and nutraceutical products include Compound Ginseng capsule, a Chinese medicine preparation that is used to cure and treat prostate gland proliferation; Nizhuanle Yin granule, a Chinese medicine preparation that treats the decomposition or inflammation of the stomach's mucous membrane; and Tianan soft capsule, which is used to adjust high amounts of fat in the blood stream, improve blood vessel ventilation, and soften blood vessels. Its products also include Tianan Pain Relief Capsule, a Chinese medicine preparation, which is under development to cure pain in joints, headache, pain from muscle injury, cancer, and gynecological disorders, as well as general pain. Tian' An Pharmaceutical sells its products to independent distributors, who sell products to pharmacies and drugstores, and hospitals. The company was founded in 2003 and is based in Xi'an, China.
- Leadership
- Jianjun Weng
- IPO Date
- Jun 22, 2007
- Employees
- 3
- Street Address
- International Trade Centre
- Mailing
- Xi'an
- Region
- Xi'an, CN
- Reporting Currency
- USD
- Investor Line
- +86 851 8381 2133
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 1258.6
- EV/EBITDA
- 30.3
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- 0.0%
- Free Cash Flow
- -173.6%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -7.4%
- ROIC
- 30.8%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.